Journal
DIGESTIVE DISEASES AND SCIENCES
Volume 59, Issue 11, Pages 2714-2720Publisher
SPRINGER
DOI: 10.1007/s10620-014-3291-3
Keywords
Pancreatic ductal adenocarcinoma; Biomarkers; Peripheral blood; Gene expression profiling; cDNA microarrays
Categories
Funding
- FEDER, Plan Nacional de Investigacion Cientifica, Desarrollo e Innovacion Tecnologica (I+D+I), Instituto de Salud Carlos III (FIS) [PI12/01935, EC08/00009]
- CEI BioTic project [mP_BS_36]
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy associated with poor survival rates. Fast detection of PDAC appears to be the most relevant strategy to improve the long-term survival of patients. Our objective was to identify new markers in peripheral blood that differentiates between PDAC patients and healthy controls. Peripheral blood samples from PDAC patients (n = 18) and controls (n = 18) were analyzed by whole genome cDNA microarray hybridization. The most relevant genes were validated by quantitative real-time PCR (RT-qPCR) in the same set of samples. Finally, our gene prediction set was tested in a blinded set of new peripheral blood samples (n = 30). Microarray studies identified 87 genes differentially expressed in peripheral blood samples from PDAC patients. Four of these genes were selected for analysis by RT-qPCR, which confirmed the previously observed changes. In our blinded validation study, the combination of CLEC4D and IRAK3 predicted the diagnosis of PDAC with 93 % accuracy, with a sensitivity of 86 % and specificity of 100 %. Peripheral blood gene expression profiling is an useful tool for the diagnosis of PDAC. We present a validated four-gene predictor set (ANKRD22, CLEC4D, VNN1, and IRAK3) that may be useful in PDAC diagnosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available